Germany – Pharmaceutical products – Open House Originals Discount Agreements 2024-12 - Tofacitinib
TenderZenith matches this tender's eligibility criteria against your company profile to calculate a deterministic qualification score and identify potential disqualifiers.
A structured breakdown of scope, eligibility requirements, submission steps, and key conditions — extracted directly from the official notice.
Sign in to unlock Bid Fit & AI Opportunity Intelligence
TenderZenith calculates a personalized qualification score against your company profile and extracts structured intelligence from tender documents with your 7-Day Pro Trial (No Credit Card Required).
Description & Project Overview
The TK pursues the goal of concluding discount agreements with all suitable pharmaceutical companies in accordance with Section 130c Paragraph 1 SGB V for the active ingredient tofacitinib. The contract is concluded as part of the TK Open House Originals procedure: individual negotiations about contract contents are not conducted; uniform conditions apply. TK does not guarantee individual contractual partners any exclusivity.
The contract term is a maximum of 28 months starting on January 1st, 2025. The contract ends on March 31, 2027 at the latest, regardless of the date the contract was concluded. Upon patent expiry/expiry